Tor 20 jun / År 42 / Nr 3 2024

Corline Biomedical Establishes Subsidiary at the AZ BioVentureHub

On July 1st, Corline Pharma started its operations at the AstraZeneca BioVentureHub in Mölndal. The aim of the newly formed company is to develop the heparin-based compounds of Corline Biomedical into in vivo administered pharmaceuticals.

Corline Biomedical AB develops heparin derived pharmaceuticals to improve cell therapies and kidney transplantation. Based on the same technology the company also manufactures and markets heparin based solutions for surface coatings of medical device implants, making them blood and biocompatible. Up to now, all of the company’s products have been used to treat devices and organs outside the patient prior to implantation.
In May 2015, the Uppsala-based company established the new subsidiary, Corline Pharma AB, for the development of its heparin-based compounds into drugs that are administered directly to the patient. This represents a major leap in Corline’s pipeline development.
”We’re active in the evolving field of regenerative medicine and view the forming of Corline Pharma as a natural step in developing Corline into a company with an increased focus on pharmaceuticals,” says Henrik Nittmar, CEO of Corline Biomedical AB.
The opportunity to establish Corline Pharma at the AZ BioVentureHub was a pre-requisite for placing the company in the Gothenburg area.
”Definitively so,” states Henrik Nittmar, firmly. ”By acting in an environment with the competence and experience present at the BioVentureHub and AstraZeneca, we expect to reduce inherent development risks in the project and that our efforts will yield results much more quickly.”

Novel In Vivo Administration
Corline Pharma will focus on developing the technology platform – Corline Heparin Conjugate (CHC™) – into pharmaceuticals for in vivo administration, which is a thing that has never been done before.
In addition to evaluating totally new indications for CHC™, Corline Pharma will coordinate the development of Corline’s manufacturing quality and control for the substances Cytoparin™ and Renaparin™.
”Big companies like AstraZeneca are very good at pre-clinical development and manufacturing quality, which is why it fits us so well to be situated at the Hub. We know that AstraZeneca have an interest in smaller companies close to clinical phase and we can hopefully contribute with some innovative concepts and new approaches,” Henrik Nittmar concludes.